Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients
Disease Markers · 21.12.2022 · 2022 · 1-13
DOI: 10.1155/2022/8766448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 21.12.2022. Verfasst von Anqi Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Carcinoma, Small Cell. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Platinum-based chemotherapy is the first choice of treatment for patients diagnosed with small lung cell cancer (SCLC). However, many patients exhibit resistance to it. Therefore, it is imperative to further investigate a prognostic biomarker indicating sensitivity to this therapy.
Methods
We collected and performed RNA sequencing on 45 SCLC samples from the Zhujiang Hospital (Local-SCLC). In addition, we used a public cohort from George et al. as a validation cohort (George-SCLC). The transforming growth factor β signaling pathway (TGFB) activation status was determined according to the related ssGSEA score. We analyzed immune cell ratios, pathway activation scores, and immune-related genes in SCLC patients to further elucidate the potential mechanisms.
Results
A high activation status of the TGFB pathway was associated with improved prognosis in SCLC patients receiving platinum-based chemotherapy (Local-SCLC: HR = 0.0238 , (95% CI, 0.13-0.84), p = 0.0238 ; George-SCLC: HR = 0.0315 , (95% CI, 0.28-0.98), p = 0.0315 ). Immune infiltration analysis showed that the TGFB-HIGH group had more M1 macrophages and Th1 cells, whilst fewer M2 macrophages, Th2 cells, and Treg cells were found in the Local-SCLC cohort. Mechanistic analysis showed that the TGBF-HIGH group was upregulated in STING-mediated immunity, apoptosis, and cell cycle arrest, as well as being downregulated in the process of DNA damage repair.
Conclusions
SCLC patients exhibiting a high activation status of the TGFB pathway demonstrate an improved prognosis with platinum-based chemotherapy. The potential underlying mechanism may be related to antitumor immune enhancement and DNA damage repair inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
- The First Clinical Medical School, Southern Medical University, 1023 Shatai South Road, Guangzhou, 510515 Guangdong, China.
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
ORCID-Profile: Jian Zhang, Peng Luo
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Lin, A., Zhu, L., Jiang, A., Mou, W., Zhang, J., & Luo, P. (2022). Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients. Disease Markers, 2022, 1-13. https://doi.org/10.1155/2022/8766448
Vancouver
Lin A, Zhu L, Jiang A, Mou W, Zhang J, Luo P. Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients. Disease Markers. 2022;2022:1-13. doi:10.1155/2022/8766448
BibTeX
@article{Lin2022,
author = {Lin, Anqi and Zhu, Lingxuan and Jiang, Aimin and Mou, Weiming and Zhang, Jian and Luo, Peng},
title = {Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients},
journal = {Disease Markers},
year = {2022},
volume = {2022},
pages = {1--13},
doi = {10.1155/2022/8766448}
}
EUVIMED